KR20170118762A - 피롤로피리딘 화합물의 결정형 - Google Patents

피롤로피리딘 화합물의 결정형 Download PDF

Info

Publication number
KR20170118762A
KR20170118762A KR1020177023996A KR20177023996A KR20170118762A KR 20170118762 A KR20170118762 A KR 20170118762A KR 1020177023996 A KR1020177023996 A KR 1020177023996A KR 20177023996 A KR20177023996 A KR 20177023996A KR 20170118762 A KR20170118762 A KR 20170118762A
Authority
KR
South Korea
Prior art keywords
pyrrolo
pyridin
bromo
piperidin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177023996A
Other languages
English (en)
Korean (ko)
Inventor
제프리 스털츠
크리스토퍼 엠. 린데만
케이쓰 엘. 스펜서
웨이동 리우
조셉 루바치
Original Assignee
제넨테크, 인크.
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55521844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170118762(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제넨테크, 인크., 어레이 바이오파마 인크. filed Critical 제넨테크, 인크.
Publication of KR20170118762A publication Critical patent/KR20170118762A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020177023996A 2015-02-26 2016-02-26 피롤로피리딘 화합물의 결정형 Withdrawn KR20170118762A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562121396P 2015-02-26 2015-02-26
US62/121,396 2015-02-26
PCT/US2016/019904 WO2016138458A1 (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Publications (1)

Publication Number Publication Date
KR20170118762A true KR20170118762A (ko) 2017-10-25

Family

ID=55521844

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177023996A Withdrawn KR20170118762A (ko) 2015-02-26 2016-02-26 피롤로피리딘 화합물의 결정형

Country Status (21)

Country Link
US (2) US20160251350A1 (cg-RX-API-DMAC7.html)
EP (1) EP3262042A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018506562A (cg-RX-API-DMAC7.html)
KR (1) KR20170118762A (cg-RX-API-DMAC7.html)
CN (1) CN107406447A (cg-RX-API-DMAC7.html)
AR (1) AR103801A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016225070A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017018230A2 (cg-RX-API-DMAC7.html)
CA (1) CA2976665A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017002180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017009662A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170439A (cg-RX-API-DMAC7.html)
HK (1) HK1246786A1 (cg-RX-API-DMAC7.html)
IL (1) IL254115A0 (cg-RX-API-DMAC7.html)
MA (1) MA41599A (cg-RX-API-DMAC7.html)
MX (1) MX2017010888A (cg-RX-API-DMAC7.html)
PE (1) PE20171327A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501532A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017133093A (cg-RX-API-DMAC7.html)
SG (1) SG11201706824TA (cg-RX-API-DMAC7.html)
WO (1) WO2016138458A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
CN108721284A (zh) * 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
CA2921956C (en) * 2013-08-22 2021-10-19 Genentech, Inc. Process for preparing (r)-5-bromo-4-(3-amino)piperidin-1-yl)-3-(cyclopropanecarboxamido)-1h-pyrrolo[2,3-b]pyridine
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds

Also Published As

Publication number Publication date
HK1246786A1 (zh) 2018-09-14
CN107406447A (zh) 2017-11-28
BR112017018230A2 (pt) 2018-04-17
CL2017002180A1 (es) 2018-03-16
IL254115A0 (en) 2017-10-31
CR20170439A (es) 2018-01-08
PE20171327A1 (es) 2017-09-12
RU2017133093A (ru) 2019-03-26
EP3262042A1 (en) 2018-01-03
WO2016138458A1 (en) 2016-09-01
AU2016225070A1 (en) 2017-09-07
US20180282324A1 (en) 2018-10-04
US20160251350A1 (en) 2016-09-01
RU2017133093A3 (cg-RX-API-DMAC7.html) 2019-08-23
PH12017501532A1 (en) 2018-02-05
CA2976665A1 (en) 2016-09-01
AR103801A1 (es) 2017-06-07
MA41599A (fr) 2018-01-02
JP2018506562A (ja) 2018-03-08
CO2017009662A2 (es) 2018-02-28
MX2017010888A (es) 2017-12-15
SG11201706824TA (en) 2017-09-28

Similar Documents

Publication Publication Date Title
US11753406B2 (en) Salts of a PD-1/PD-L1 inhibitor
TWI918605B (zh) 作為治療劑之細胞毒素之肽結合物
CN120548318A (zh) Kras g12d抑制剂和其用途
EP2729448B1 (en) Compounds for the treatment of hiv
CN121752574A (zh) Kras抑制剂和其用途
CA3115609C (en) Processes of making and crystalline forms of a mdm2 inhibitor
CN107660202B (zh) 水溶性前药
WO2016131414A1 (zh) 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
JP2025538506A (ja) がんの治療のための縮合ピリジンの固体形態
CN111386275B (zh) 高活性sting蛋白激动剂
TWI820437B (zh) 亞磺醯基胺基苯甲醯胺與磺醯基胺基苯甲醯胺之衍生物
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
JP7772899B2 (ja) ニコチニルアルコールエーテル誘導体のマレイン酸塩、その結晶形、及びその使用
CN115385894A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
CN106279121A (zh) 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
WO2021227938A1 (zh) 含非甾体抗炎药结构的氨基酸衍生物及其制备方法与应用
JP6280543B2 (ja) N−((s)−2,3−ジヒドロキシ−プロピル)−3−(2−フルオロ−4−ヨード−フェニルアミノ)−イソニコチンアミドの固体形態
WO2015113521A1 (zh) 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
CN106458886A (zh) 药物活性化合物的固体形式
WO2018028491A1 (zh) 吲哚胺2,3-双加氧酶抑制剂及其在药学中的用途
KR20150060610A (ko) 다이하이드로피리미딘 유도체의 결정질 형태
WO2017128036A1 (zh) 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途
CN107406447A (zh) 吡咯并吡啶化合物的结晶形式
CN116813646A (zh) 取代桥环类抑制剂及其制备方法和应用
CN118908998A (zh) 抗病毒前药及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170828

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination